TW
Troy Edward Wilson (President and CEO) filed 2 Form 4 reports in the trailing twelve months (2 purchases, 0 sales), most often in Kura Oncology, Inc. (KURA). Across 2 priced purchase filings, the average 21-session return was +1.5% from execution and +1.5% from disclosure (delay-adjusted; derived). The largest single filing was $1.2M of KURA (100,000 sh × $12.39, as filed), executed Aug 24. Data as of Nov 8 2026.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
+1.5%
avg across 2 priced filings
Delay-adjustediThe same average, entered at disclosure dates
+1.5%
same 2 filings, from disclosure
Filings, ttm
2
2 buys · 0 sells
Median delay
0d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$2.4M
shares × price, as filed
Last traded
Aug 24
Filed Aug 24
Median ADV $20.0M across their filed names
Open performance→Volume by month
Buys $3.0M
Sells $6.1M
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
2 filings
Sector per market data · by filing · past 12 months
Most traded names
KURA
Kura Oncology, Inc.
KURA · 4 buys · 1 sell
5 filings
RNA
RNA
0 buys · 2 sells
2 filings
Recent filings
KURAPURCHASE
Kura Oncology, Inc.
View filing →
$1.2M100,000 sh × $12.39
Exec Aug 24
Filed Aug 24 · 5:30 PM ET KURAPURCHASE Kura Oncology, Inc. View filing → $1.1M
100,000 sh × $11.12
Exec Aug 17
Filed Aug 17 · 4:45 PM ET KURASALE Kura Oncology, Inc. View filing → $327K
36,615 sh × $8.94
Exec Sep 29 2025
Filed Sep 29 2025 · 5:30 PM ET KURAPURCHASE Kura Oncology, Inc. View filing → $410K
50,000 sh × $8.20
Exec Sep 8 2025
Filed Sep 9 2025 · 4:28 PM ET RNASALE Avidity Biosciences, Inc. View filing → $1.5M
29,500 sh across 2 lots
Exec Sep 5 2025
Filed Sep 9 2025 · 5:30 PM ET KURAPURCHASE Kura Oncology, Inc. View filing → $214K
36,506 sh × $5.85
Exec Aug 12 2025
Filed Aug 14 2025 · 4:05 PM ET RNASALE Avidity Biosciences, Inc. View filing → $4.3M
95,054 sh across 6 lots
Exec Aug 6 2025
Filed Aug 8 2025 · 5:30 PM ET